title: Rituximab-induced pulmonary disease.
authors: Mortimer B
authors: MB
authors: O'Connor
authors: Mohamad Fadri Bin
authors: MF
authors: Abdullah
authors: Neil
authors: N
authors: O'Donovan
authors: Mark J
authors: MJ
authors: Phelan
mesh_terms: D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab; D019980:Amoxicillin-Potassium Clavulanate Combination; D011239:Prednisolone; D017291:Clarithromycin; D006854:Hydrocortisone